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Abstract 
Erythropoiesis must be tightly balanced in order to guarantee adequate oxygen delivery to all 
tissues in the body. This process relies predominantly on the hormone erythropoietin (EPO) and 
its transcription factor hypoxia inducible factor (HIF). Accumulating evidence suggests that 
oxygen-sensitive prolyl hydroxylases (PHDs) are important regulators of this entire system. 
Here, we describe a novel mouse line with conditional PHD2 inactivation (cKO P2) in renal EPO 
producing cells, neurons and astrocytes that displayed excessive erythrocytosis due to severe 
over-production of EPO, exclusively driven by HIF-2α. In contrast, HIF-1α served as a 
protective factor, ensuring survival of cKO P2 mice with hematocrit values up to 86%. Using 
different genetic approaches, we show that simultaneous inactivation of PHD2 and HIF-1α 
resulted in a drastic PHD3 reduction with consequent overexpression of HIF-2α-related genes, 
neurodegeneration and lethality. Taken together, our results demonstrate for the first time that 
conditional loss of PHD2 in mice leads to HIF-2α-dependent erythrocytosis, whereas HIF-1α 
protects these mice, providing a platform for developing new treatments of EPO-related 
disorders like anemia. 
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Introduction 
Erythropoietin (EPO) is the primary regulator of red blood cell formation and its expression level 
is extremely responsive to fluctuations in tissue oxygenation. Dysregulation of EPO production 
can lead to either anemia, if levels are inadequately low, such as in terminal kidney failure or to 
erythrocytosis if levels are inappropriately high. Erythrocytosis will develop when EPO is 
continuously overproduced, causing the generation of new erythrocytes at a rate exceeding the 
removal of senescent red blood cells.
1
 In adult animals the main physiological source of EPO is 
the kidney, although the liver as well as the central nervous system (CNS) have also been shown 
to produce EPO but to a much lesser extent.
2,3
 The main physiological stimulus of EPO 
production is tissue hypoxia in the interstitium of the kidney.
4
 Already two decades ago it was 
shown that this effect was dependent on binding of the transcription factor hypoxia inducible 
factor (HIF) to 5’- and 3′-enhancer regions of the EPO gene, known as the hypoxia responsive 
element (HRE).
5
  
HIF is a heterodimeric complex composed of an oxygen-sensitive HIFα and a constitutive HIFβ 
subunit. Of the most intensively studied HIF-α genes, HIF-1α has a ubiquitous pattern of 
expression in all tissues,
6
 whereas expression of the paralogue HIF-2α is restricted to certain cell 
types.
7,8
  However, both factors actively promote oxygen delivery and adaptive processes to 
hypoxia such as erythropoiesis, angiogenesis, anaerobic glycolysis and hematopoiesis.
1,9-11
 
Oxygen-sensing is therefore indispensable as it enables the cells to instantaneously adapt to an 
inappropriately low pO2. This machinery relies on the HIF-prolyl hydroxylases (PHD1-3), 
enzymes that hydroxylate and, consequently, lead to the inactivation of HIFα in the presence of 
oxygen.  
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PHD2 is believed to be the crucial oxygen sensor during normoxia and mild hypoxia,
12
 which is 
underscored by the fact that inactivation of PHD2 severely deregulates normal embryonic 
development resulting in embryonic lethality by E14.5, whereas PHD1-/- or PHD3-/- mice 
develop normally.
13
 Moreover, even haplodeficient PHD2+/- mice show normalization of the 
endothelial lining during tumor development compared to wild type controls.
14
 In humans, 
several heterozygous point mutations in the PHD2 gene have been described, which lead to an 
absolute increase in red blood cell mass. These are in some cases associated with severe clinical 
conditions like hemorrhage, stroke and increased risk of thrombosis,
15-18
 although the latter was 
shown to be independent of elevated hemoglobin/hematocrit.
19
 PHD2 is therefore the main HIF 
prolyl hydroxylase isoform which, next to HIF-2α and the von Hippel-Lindau protein (VHL), 
controls the expression of EPO in humans
20
. In spite of the above, the role of PHD2 in the 
etiology of erythrocytosis and related disorders has not been extensively studied. Indeed, 
systemic PHD2 heterozygosity in mice shows only a very mild induction of hematocrits
14
, 
whereas somatic inactivation shortly before or after birth leads to severe erythrocytosis and early 
lethality.
21,22
  
In this report, we describe a new conditional PHD2 mouse line expressing cre-recombinase 
under the control of the modified human CD68 promoter, commonly defined as a 
monocyte/macrophage marker.
23
 In addition, we found PHD2-loss in other cell lineages, 
resulting in excessive HIF-2α-induced EPO production in kidney and brain, extreme hematocrits 
up to 86%, thrombocytopenia and splenomegaly, but survival of the mice in a HIF-1α-dependent 
manner. Additional inactivation of HIF-1α (PHD2/HIF-1α double knockout) leads to early 
lethality around adulthood, which is confined to PHD3-reliant HIF-2α-overstabilization and 
consequent neurodegeneration in the brain.  
5 
 
Taken together, our results establish a principal role for PHD2 as an oxygen sensor in CD68-
positive cells for the HIF-2α-dependent regulation of EPO and highlight a protective role of HIF-
1α in polycythemic mice. 
 
 
Methods 
Generation of a CD68:cre line  
The modified hCD68-IVS1 promoter,
23
 which combines the 2940 bp of sequence 5’ to the ATG 
and the 83-bp first intron of the human CD68 gene was cloned just in front a codon-improved 
Cre recombinase sequence (1091 bp)
24
 and a polyA signal. Different founders were produced 
and tested on expression levels in isolated peritoneal F4/80
+
 cells. Finally, two lines were 
selected of which one expressed cre-recombinase already in sperm as well as egg cells. The other 
transgenic line was intercrossed with PHD2
f/f 
mice and used in the current report. 
 
Mice 
All mice were housed at the Experimental Centre at the University of Technology Dresden 
(Medical Faculty, University Hospital Carl-Gustav Carus), under specific pathogen-free 
conditions. Experiments were performed with male and female mice at the age of 8-12 weeks or 
as stated in the text. All mice described in this report were born in a normal Mendelian manner. 
HIF-2α f/f mice were obtained from The Jackson Laboratories (Bar Harbor, Maine) and originally 
produced in the research group of Dr. C. Simon
25
. All mouse strains were at least nine 
generations backcrossed to C57BL/6. Mice were genotyped using primers described in Table S1. 
The construction and identification of the PHD2
f/f 
mouse line will be described elsewhere (R.P.S, 
K.F., J.K., S.M., A.M., B.W. unpublished results).  
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More than 60% of all CD68:cre-PHD2
f/f 
(cKO P2), CD68:cre-PHD2/HIF-1αff/ff (cKO P2/H1) 
and CD68:cre-PHD2/PHD3
ff/ff
 (cKO P2/P3) mice showed redness of snout/paws associated with 
high hcts (> ~70%) and were used for the described experiments. Non-erythrocytotic cKO, cKO 
P2/H1 and P2/P3 mice all showed hematocrits comparable to WT littermates (<55%), which was 
always related with lower penetrance of cre-recombinase activity and were only used for 
breeding. No cKO mice were found with hematocrits between 55 and 70%.  Penetrance in cKO 
P2/H1, CD68:cre-PHD2/HIF-2αff/ff (cKO P2/H2), CD68:cre-PHD2/PHD3ff/ff (cKO P2/P3), 
CD68:cre-HIF-1αf/f (cKO H1) and CD68:cre-HIF-2αf/f (cKO H2) mice was defined via qRT-PCR 
on BM mRNA and/or genomic PCR on ear biopsies. Knock-down efficiencies for HIF-1α and 
HIF-2α in these genotypes were comparable to expression levels for PHD2. It is noteworthy that 
only a low percentage (~20%) of cKO P2/H2 mice showed cre activity with high penetrance on 
both alleles simultaneously. Only these mice were considered for the presented experiment. All 
other mice, carrying CD68:cre-PHD2
f/f
 and HIF-2αf/f, showed no targeting or only of one of the 
alleles. All animal experiments were in accordance with the facility guidelines on animal welfare 
and were approved by the Landesdirektion Dresden, Germany. 
 
Blood analysis 
Blood parameters (hematocrit, RBCs, Hb and thrombocytes) were measured using a Sysmex 
automated blood cell counter (Sysmex XE-2100 and XE-5000). Plasma erythropoietin and 
thrombopoietin concentrations were determined using the Quantikine Mouse/Rat EPO 
immunoassay and the Quantikine Mouse Tpo immunoassay (R&D Systems). 
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Blood pressure and heart rate were measured non-invasively with the tail cuff method (UGO 
BASILE). After training of the animals for two weeks, the average of at least two independent 
measurements was calculated. 
 
Cells 
The human kidney cell line REPC was cultivated as described previously.
26
 Astrocytes were 
isolated from the cerebral cortex of five day old pups by incubation with 0.025% Trypsin for 30 
minutes, followed by enrichment with the biotinylated anti-GLAST (ACSA-1) antibody 
(Miltenyi Biotec) and magnetic beads. The highly enriched astrocyte fraction (purity >90%) was 
confirmed via FACS (data not shown). 
 
Isolation of individual cell types  
Primary mouse keratinocytes and fibroblasts were isolated from newborn mice by incubating the 
skin with 250mg/ml Dispase (Roche) overnight at 4°C. The epidermal layer was separated from 
the dermal layer and incubated in TrypLE select enzyme (Invitrogen) for 30 min at RT. The 
resulting single cell suspension was cultured in CnT medium (Cell-n-Tech). The dermal layer 
was finely minced and then incubated in a 0.25% trypsin / EDTA solution (Gibco) for 30 min at 
37°C. The resulting cell suspension was cultured in DMEM (Lonza) containing 10% FBS 
(Biochrom), 1% L-Glutamine (Lonza) and 1% penicillin/streptomycin (Lonza). Identity of 
keratinocytes was confirmed via Keratin6 (K6) staining (data not shown). Enterocytes were 
isolated from 2 cm of colon starting from the caecum. The colon was cut into 5-6 pieces and 
incubated in Cell Recovery Solution (BD Biosciences) for 1.5 h at 4°C. After vigorous shaking, 
the cell suspension was filtered, centrifuged, and the resulting cell pellet frozen. Identity of the 
8 
 
enterocytes (colonocytes) was confirmed via Villin1 staining (data not shown). Endothelial cells 
were isolated from the lung via FACS (CD31
+
CD34
+
) and confirmed on the basis of CD31 
mRNA expression (data not shown). 
 
Expression analysis 
RNA from organs and sorted cells was isolated using RNeasy Mini Kit (Qiagen), NucleoSpin 
RNA XS (Machery-Nagel), Trizol (Invitrogen), Universal RNA Purification Kit (roboklon) or 
DNA+RNA+PROTEIN Purification Kit (roboklon). cDNA was synthesized using random 
primers (Roche) and SuperScript II (Invitrogen). Expression levels were determined by 
performing quantitative Real-time PCR using the Maxima SYBR Green QPCR Master Mix 
(Fermentas) on an iCycler iQ (Biorad). Sequences of primers used are given in Table S2. 
Expression levels were normalized with the ΔΔCt method using primers given in Table S3. 
 
Histology and immunofluorescence  
For all samples, organs were placed in 4% formaldehyde at 4°C overnight, dehydrated, 
embedded in paraffin and cut. Sections were rehydrated and subjected to hematoxylin and eosin 
staining or acidic Fuchsin orange G-staining. For IHC, antigen retrieval (citrate buffer-PH 6.0) at 
95°C for 20 minutes was performed on rehydrated sections. Incubation with primary antibody 
(Ab) ((Iba1 (WAKO), cleaved-Caspase3 (Cell Signaling), NeuN (Abcam)) was 1.5h at 37°C. 
Secondary Ab were Alexa-488 or Alexa-568 (Molecular Probes) incubated for 30 min. at RT.  
Cell nuclei were stained with DAPI. Slides were mounted with fluorescent mounting media 
(Dako). For frozen sections, samples were embedded in OCT, cut and stored at -20°C. For 
immunofluorescence staining, sections were first fixed for 10 min in cold acetone and blocked 
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with 5% goat serum in TNT buffer (20mM Tris pH 7.6, 0.9% NaCl, 0.05% Tween in PBS). 
Thereafter, sections were incubated with mouse anti-NeuN and rabbit anti-PHD2 at 37°C for 1h 
(custom-made polyclonal rabbit anti-mouse antibody against a C-terminal peptide of PHD2 
(EKGVRVELKPNSVSKDV) and purified via a peptide sulfoLink immobilization column 
(Pierce, ThermoScientific, IL)). Secondary antibody as described above. 
 
Microscopy 
Fluorescent and light microscopy was done with an Axioplan-2 imaging microscope and plan 
Apochromat lenses (Carl Zeiss). The cameras and acquisition software were either Q Imaging 
Retiga 2000R and Image pro MC6.0 (fluo) or Axiocam MRc5 and Axiovision (light). Image 
processing and analysis was done using ImageJ and the ImageJ distribution Fiji 
(http://pacific.mpi-cbg.de/wiki/index.php/Fiji).  
 
Flow cytometry  
FACS analysis was performed on LSRII (Becton Dickinson), sorting was done on Aria II 
(Becton Dickinson). Cell numbers were counted on MACS quant (Miltenyi). Data was analyzed 
on DIVA (Becton Dickinson), MACS quantify (Miltenyi) or Flowjo (Treestar) software. BM 
single cell suspensions were made by flushing the marrow using 23G needles. Single cell 
suspensions from spleen and lymph nodes were prepared by manual disruption using frosted 
slide ends, additionally for spleen cells enzymatic digestion was performed with 0.3U/ml 
Collagenase D (Roche) for 40 min at 37°C. The lineage cocktail included CD3 (145-2C11, 
eBioscience), CD19 (eBio1D3, eBioscience), NK1.1 (PK136, eBioscience), Ter119 (Terr119, 
eBioscience), CD11b (M1/70, eBioscience), Gr1 (RB6-8C5, eBioscience), B220 (RA3-6B2, 
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eBioscience), CD127 (A7R34, eBioscience), CD11c (N418, eBioscience). For MEP analysis, 
spleen and bone marrow cells along with lineage cocktail were also incubated with c-kit (APC, 
2B8, eBioscience), Sca1 (Pe-Cy7, D7, eBioscience), CD16/32 (A700, 93, eBioscience), CD34 
(FITC, RAM34, eBioscience), SA (PerCP, BD Biosciences). 1 x10^6 cells from bone marrow 
and 2 x10^6 cells from spleen were acquired. For EB analysis, spleen and bone marrow cells 
were stained with CD71 (FITC, R17217, eBioscience) and Ter119 (Pe-Cy7, Ter119, 
eBioscience). 2 x 10^5 cells were acquired. For lymphoid cell analysis, spleen and lymph node 
cells were incubated with CD3 (APC, 145-2c11, eBioscience) and CD19 (FITC, MB19-1, 
eBioscience). For myeloid cell analysis, spleen cells were incubated with CD11b (PE, M1/70, 
eBioscience), F4/80 (PerCP-cy5.5, BM8, eBioscience) and/or Gr1 (A700, RB6-8C5, 
eBioscience).  
 
Blood volume determination  
Blood was collected in EDTA vials, washed twice with 0.9% NaCl, and stained with 15uM 
Vybrant DiI Cell-labeling solutions (Invitrogen) for 2.5h at RT on a tilt shaker. After washing 
and re-suspension in PBS 100ul was injected intravenously. One hour later a blood sample was 
taken from the mouse, diluted and analyzed for DiI containing cells.  
 
Statistical analysis  
Data and graphs represent mean ± SEM of representative experiments. Statistical significance 
was calculated as two-tailed by the Mann Whitney U test (GraphPad Prism v5.04), with p<0.05 
considered statistically significant. 
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Results 
Conditional PHD2 deficient mice display severe HIF-2α-dependent erythrocytosis  
PHD2 is the main HIF prolyl hydroxylase isoform, which controls the expression of EPO in 
humans.
20
 Somatic inactivation of PHD2 shortly before or after birth leads to severe 
polycythemia probably in a HIF-1α-dependent manner but is accompanied by early lethality and 
has therefore not been extensively studied.
21,22
 To conditionally ablate PHD2, we first generated 
a PHD2
f/f 
mouse line by gene targeting using a construct in which Exons 2 and 3 are flanked by 
loxP sites (R.P.S, K.F., J.K., S.M., A.M., B.W. unpublished results). We combined this with a 
newly designed mouse line expressing cre-recombinase under the control of the modified human 
CD68 promoter, known as a monocyte/macrophage marker (Supplemental Figure 1A). Thorough 
analyses revealed that these cKO P2 mice are not only significantly deficient for PHD2 in 
macrophages, but in the entire hematopoietic system (bone marrow) (Supplemental Figure 1B). 
In addition, we also found a profound PHD2 reduction in a few subsets of epithelial cells (e.g. 
keratinocytes and colonocytes), but not in other cell lineages like endothelial cells (ECs) and 
fibroblasts (Supplemental Figure 1C). In the lysates of non-hematopoietic organs studied in the 
current report, we found no significant reduction of PHD2 expression (Supplemental Figure 1D). 
Moreover, no significant compensation by one of the other PHDs could be shown (Supplemental 
Figure 1E) 
Interestingly, the majority of these cKO P2 mice showed obvious redness of paws and snout 
starting around 4 weeks of age, which was accompanied by significant growth retardation until 
adulthood (Figure 1A-B). This striking phenotype was due to elevated hematocrits which 
increased with age to >85% in some individuals (Figure 1C). However, although the blood 
viscosity was substantially increased, we observed no difference in the blood pressure, heart rate 
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or cardiac hypertrophy, as has been shown before for other erythrocytotic mice (Supplemental 
Figure 2A-B).
27
 As PHD2 can control the activity of both HIF-1α and HIF-2α we determined 
which of the HIFs contributed to the erythrocytosis. The notion that HIF-2α acts as the main 
regulator of EPO is based on histological and genetic approaches in HIF-2α deficient mice.10,25,28 
Moreover, several studies in patients with idiopathic erythrocytosis revealed the presence of 
different heterozygous missense mutation in the coding sequence of HIF-2α, but not HIF-1α, 
leading to impaired PHD2-induced hydroxylation.
29,30
 On the other hand, a somatic knockout of 
PHD2, suggested that HIF-1α, rather than HIF-2α, contributed to increased renal EPO 
synthesis.
21
 To unequivocally determine the major regulator in the erythrocytotic cKOs, we 
therefore generated mice double deficient for PHD2 and HIF-1α or HIF-2α. Our data 
demonstrate that the erythrocytosis phenotype as shown in cKO P2 mice was abolished in 
CD68:cre-PHD2/HIF-2αff/ff mice (cKO P2/H2), displaying even significantly lower hematocrits 
and hemoglobin levels than in WT mice (Figure 1D-F). On the other hand, hematocrits in 
CD68:cre-PHD2/HIF-1αff/ff mice (cKO P2/H1) were indistinguishable from cKO P2, showing 
that PHD2-induced severe erythrocytosis is exclusively dependent on HIF-2α but not on HIF-1α. 
These results are emphasized by the fact that conditional knock-down of HIF-2α alone 
(CD68:cre-HIF-2αf/f (cKO H2)), but not HIF-1α (CD68:cre-HIF-1αf/f (cKO H1)), already 
resulted in a mild anemia (Supplemental Figure 3A-C).  
 
Erythrocytosis is EPO dependent and associated with increased EPO expression in kidney 
and brain 
Since excessive secondary erythropoiesis is mainly mediated by erythropoietin (EPO),
27
 we 
measured EPO plasma levels in both erythrocytotic mouse lines (cKO P2 and cKO P2/H1) and 
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found a highly significant induction of EPO expression in cKO P2 mice compared to WT 
littermates. Surprisingly, although cKO P2/H1 mice showed similar hematocrits to cKO P2 mice, 
they contained on average 2.5-fold higher plasma EPO values than cKO P2 mice (Figure 2A). 
The main source of EPO in adult mice is the kidney,
3
 where we found a 10-fold and 20-fold 
increase of EPO in extracts from cKO P2 and from cKO P2/H1 mice, respectively. Additionally, 
the expression of EPO in the brain was significantly up-regulated (Figure 2B). In contrast, 
hepatic EPO expression levels were very low, and no increase could be observed in any of the 
mice (data not shown).  
In the kidney, EPO is produced by specialized interstitial cells localized in the deep cortex 
between the proximal tubular and vascular endothelial cells. These renal EPO producing (REP) 
cells also express neuronal-specific markers but isolation of these primary cells has been a real 
challenge so far.
31
 Therefore, we tested the recently described human REP cell line, isolated 
from the tumor-free tissue of a male patient
26
 and demonstrate that these cells co-expressed both 
CD68 and EPO, supporting the link between CD68-driven cre expression, PHD2 inactivation 
and subsequent EPO expression in our cKO P2 mice (Figure 2C). In the brain, astrocytes and 
neurons are known to be sources of EPO.
32
 We therefore isolated astrocytes from the cerebral 
cortex of five day old pups and found a significant PHD2 reduction in cKO P2 cells versus WT 
(Figure 2D). The latter result was similar to the knockdown efficiency found in other cell types 
(Supplemental Figure 1B-C). Via IHC we demonstrate that sections from adult cKO P2 brains 
contain a majority of PHD2-negative cells that were positive for the neuronal marker NeuN 
(Figure 2E).  
Moreover, since cKO P2 mice are also deficient for PHD2 in the BM, we transplanted BM cells 
from cKO P2 mice into lethally irradiated WT mice and vice-versa. However, we found no 
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significant difference in hematocrit compared to non-transplanted animals, thus excluding the 
possibility that the phenotype could be transferred with PHD2-deficient hematopoietic cells 
(Figure 2F).  
Taken together, the erythrocytosis phenotype in cKO P2 and cKO P2/H1 mice is correlated with 
an enormous induction of EPO in the kidney and the brain, related to PHD2 inhibition in REP 
cells, astrocytes and neurons.  
 
Erythrocytosis is mainly caused by extramedullary erythropoiesis. Basal erythropoiesis 
mainly takes place in the bone marrow whilst the spleen can increase its capability to produce 
RBCs under conditions of stress erythopoiesis.
33
 In the cKO P2, polycythemia resulted in 
splenomegaly accompanied by loss of splenic architecture, with an increase in nucleated cells 
and total weight (Figure 3A-C). Remarkably, the megakaryocyte-erythroid progenitors (MEPs) 
were found to be significantly induced (>2.5 fold) in the spleen of cKO P2 mice but not in BM 
(Figure 3D-E). In addition, splenic CD71
+
/Ter119
+
 erythroblasts (EBs) were increased more than 
10-fold in cKO P2 mice compared to WT littermates, whereas only a mild increase in EBs was 
found in BM (Figure 3F-G). The fraction of B- and T-cells were markedly decreased in the cKO 
P2 spleen while lymph nodes contained an excess of both populations, suggesting that there is no 
impairment of their production but only a difference in localization due to the EB excess in the 
spleen (Supplemental Figure 4A-D). Splenic CD11b
+
F4/80
+
 macrophages and neutrophils 
(PMNs) were not significantly altered, although red pulp macrophages, a distinct subset of 
macrophages involved in the removal of senescent erythrocytes, were highly induced in the cKO 
P2 spleen (Supplemental Figure 4E-G). These results imply that the spleen is primarily 
responsible for the overproduction of RBCs in cKO P2 mice. 
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Thrombocytopenia is directly related to the higher blood volume 
Further hematological analysis revealed a significant decrease in platelet numbers in cKO P2 
mice compared to WT mice, as early as at 4 weeks of age (Figure 4A). This effect was also 
related to HIF-2α but not HIF-1α, since the phenotype was rescued only in the cKO P2/H2 mice 
(Figure 4B). To examine the molecular background of this effect we analyzed different 
parameters but found no relative difference in thrombopoietin (TPO), the number of 
megakaryocytes in the BM or spleen (Supplemental Figure 5A-C), nor did we detect micro-
vascular thrombosis, which would have indicated increased consumption of platelets (Figure 4C-
D). However, using flow cytometry on labeled RBCs, we found that the total blood volume in 
cKO P2 mice was significantly increased by about 65% (Figure 4E); strongly suggesting that the 
reduced platelet count is a dilution effect. 
 
cKO P2 mice display a normal life span whilst cKO P2/H1 die early. One common feature of 
the somatic PHD2 deficient mice
21,22
 as well as other EPO-related erythrocytotic mice
34,35
 is that 
these mice die prematurely. Surprisingly, we never observed any premature death in our cKO P2 
mice. Moreover, we did not encounter any lethality in a group of nine erythrocytotic cKO P2 
mice that were maintained for over twenty months. These mice were bled every four months but 
no significant drop in hematocrit could be observed (Figure 4F). Finally, all mice were sacrificed 
and several organs examined in great detail. Except for a regressing cyst associated with the 
ovary of one mouse (Supplemental Figure 6A), no obvious pathological defects or tumors were 
detected (Supplemental Figure 6B). On the other hand, the cKO P2/H1 mice started to die very 
sudden from week five onwards, and by week sixteen 95% of these mice were dead (mean 
16 
 
survival time: 11 weeks) (Figure 4G). In contrast, neither cKO P2/H2 nor cKO H1 or H2 mice 
showed any premature death. Importantly, these results show for the first time that extremely 
high hematocrits do not necessarily lead to lethality or pathological abnormalities in part due to a 
protective function of HIF-1α. 
 
Simultaneous loss of PHD2 and HIF-1α in the brain leads to neurodegeneration  
In order to investigate the biological background of the early lethality of cKO P2/H1 mice, we 
conducted a thorough examination of 8-10 week old living as well as recently-deceased cKO 
P2/H1 mice. No acute cardiovascular complications or obvious evidence for thrombosis or 
degeneration in different examined organs were observed (data not shown). However, via IHC 
staining we detected a dramatic induction of activated (Iba1
+
) microglia cells in the brain of cKO 
P2/H1 mice compared to WT and cKO P2 mice (Figure 5A-C). This strongly suggests that 
pathological changes in cKO P2/H1 brains led to the activation of these resident macrophages. 
Consistent with this, we found numerous patches of neurons (NeuN
+
) in cKO P2/H1 brain 
sections, especially from freshly deceased mice, that showed strong expression of cytoplasmic 
cleaved-caspase3 (Cl-Casp3), indicative of apoptosis (Figure 5D-F). In contrast, no Cl-Casp3 
staining could be detected in cKO P2 or WT brains (data not shown). In line with the observed 
phenotype, we found that some (3 out of 16) of the cKO P2/H1 mice even displayed a dome-
shaped skull accompanied by a dramatic hydrocephalus (Supplemental Figure 7A-B). 
To unravel the molecular background of this neurodegeneration, we compared the gene profiles 
of cKO and cKO P2/H1 brains. Remarkably, PHD3, a HIF-1α -regulated gene and formerly 
identified as a very potent negative regulator of HIF-2α,36 was drastically down-regulated in 
cKO P2/H1 brains compared to cKO P2 counterparts. Conversely, we found a significant 
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induction of pro-inflammatory cytokines like TNFα, Il-1α and IL-1β, as well as VEGFA, TGFβ1, 
CXCR4 and adrenomedullin (Adm) (Figure 5G), many of which have been shown to be HIF-2α-
dependent genes.
37
 These data therefore suggest that knocking out HIF-1α in addition to PHD2 
in a subset of brain cells (e.g. astrocytes and microglia cells) leads to an additional stabilization 
of HIF-2α and consequent transcriptional activation of a variety of genes, including detrimental 
inflammatory cytokines that can contribute to neurodegeneration and lethality of the cKO P2/H1 
mice.  
To evaluate whether HIF-1α-induced PHD3-expression is directly related to the protection of 
cKO P2 mice, we developed mice lacking PHD2 and PHD3
13
 in CD68
+
 cells (CD68:cre-
PHD2/PHD3
ff/ff
 (cKO P2/P3)). Interestingly, these mice did not only display severe 
erythrocytosis (Figure 6A); a majority of them suddenly died starting shortly after birth (Figure 
6B), whereas cKO P2 as well as PHD3
-/-
 mice never died during this period. Furthermore, we 
isolated the brains of these cKO P2/P3 mice and analyzed the same array of genes as we studied 
for the cKO P2/H1 animals. Interestingly, we found that virtually all differentially expressed 
genes in brain lysates from cKO P2/H1 mice are also significantly changed in the brains of cKO 
P2/P3 mice, compared to cKO P2 (Figure 6C). These data strengthen our hypothesis that PHD3 
is a not only a protective factor in the brain of cKO P2 mice, but acts downstream of HIF1α. 
Taken together, these results reveal a tight and essential balance between HIF-1α and HIF-2α 
activity in the brain, which also involves the PHD3 regulation.  
 
Discussion 
In the current study we used a genetic approach to investigate in detail the biological role of 
PHD2 in CD68-positive cells and the relation of two of its substrates (HIF-1α and HIF-2α) with 
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erythropoietin production and during erythropoiesis. We have demonstrated that conditional 
PHD2 deficient mice are able to cope with extreme numbers of RBCs, thrombocytopenia and 
splenomegaly through a discrete interplay between HIF-1α and HIF-2α involving the regulation 
of PHD3.  
Although CD68 has been described as a marker mainly limited to monocytic cells,
23
 our data 
demonstrate at least temporary expression in the hematopoietic compartment as well as in 
subsets of epithelial lineages, but not in ECs or fibroblasts. Moreover, our results demonstrate 
loss of PHD2 in a subset of renal and brain cells responsible for the production of EPO, which 
leads to massive stress erythropoiesis primarily executed by the adult spleen. Remarkably and in 
clear contrast to many other reports,
3,21,22,35
 our erythrocytotic cKO P2 mice show normal 
lifespan, demonstrating that an unusual high hematocrit is not per se lethal; a phenomenon that 
has also been described in a few healthy cobalt miners at high altitude that developed 
hematocrits ranging from 75-91%.
38
 Genetically, a number of heterozygous PHD2 missense 
mutations have been defined in patients, which impair the binding to both HIF-1α and HIF-2α 
resulting in erythrocytosis.
15-18
 One patient with such a PHD2 mutation and consequent 
polycythemia developed a paraganglioma, suggesting that PHD2 may act as a tumor suppressor.
1
 
However, our results strongly suggest that sustained exposure to high levels of EPO and 
permanent loss of PHD2 in different cell types does not necessarily lead to spontaneous tumor 
development over a period of 20 months in mice. This has also been underscored by recent work 
from our group showing that silencing of PHD2 in several tumor lines typically leads to reduced 
tumor growth.
39
 
In mice, we (K.F. and B.W., unpublished data) and others
14
 have shown that PHD2 
heterozygosity only results in a very mild form of erythrocytosis whereas global inactivation just 
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before or after birth leads to severe and lethal polycythemia.
21,22
 Based on expression levels in 
the kidney of the latter mice, it was proposed that HIF-1α, rather than HIF-2α, might be the 
central erythrocytosis mediator in relation to PHD2.
21
 However, our genetic approach 
(PHD2/HIFα double deficient mice) clearly shows that this phenotype is driven by HIF-2α. The 
notion that only HIF-2α induces EPO is not new,25,28 and is in line with observations from Percy 
and colleagues in familial erythrocytosis.
29,30
 However, to the best of our knowledge this is the 
first report that shows that PHD2-induced severe erythrocytosis is exclusively dependent on 
HIF2α and not on HIF1α. In addition, the finding that CD68:cre-HIF-2αf/f mice were mildly 
anemic emphasizes the importance of this HIF-subunit and confirms the, at least temporary, 
activity of CD68, in specialized EPO-producing cells.  
Simultaneous ablation of PHD2 and HIF-1α on the other hand led to early lethality, clearly 
demonstrating that HIF-1α acts as a crucial survival factor in the erythrocytotic cKO P2 mice. In 
particular, detailed analysis of mature cKO P2/H1 mice showed pathological defects only in the 
brain, a feature that was underlined by the severe hydrocephalus we observed in a few of the 
cKO P2/H1 mice. We found that a vast majority of cKO P2/H1 mice contained activated 
microglia cells and patches of apoptotic neurons, the latter especially evident in recently-
deceased mice. A gene-expression profile of individual brains showed clear induction of 
different pro-inflammatory cytokines (e.g. TNFα and IL-1β) in cKO P2/H1 mice compared to 
cKO P2 mice. These cytokines are known as main contributors in several neurodegenerative 
disorders and are typically produced by glia cells, including microglia and astrocytes, as well as 
neurons.
40-43
 Additionally, the vascular growth factor VEGFA,
44
 the chemokine receptor 
CXCR4,
45-47
 and the multifunctional growth factor TGFβ1,48,49 were over-expressed in cKO 
P2/H1 brains, and are related to the initiation and/or secondary phase of neurodegeneration. 
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Interestingly, many of these genes, including EPO, have been described as HIF-2α-related 
genes,
25,37
 suggesting that loss of HIF-1α enhances HIF-2α activity, causing brain damage as 
well as lethality of these mice. This idea is further supported by the observation that the HIF-1α -
inducible gene, PHD3, and known to be an excellent negative regulator of HIF-2α,36 is down-
regulated in the brain of cKO P2/H1 compared to cKO P2 mice. In addition, cKO P2/P3 mice 
also display severe erythrocytosis, die prematurely and show a similar induction of the array of 
genes induced in the brain of cKO P2/H1. This strongly suggests that PHD3 is an essential gene 
downstream of HIF-1α that protects cKO P2 mice and is not just just fine-tuning the HIF 
response.
50
 Taken together, this strongly suggests that HIF-1α in a subset of cells in the brain, 
including microglia, neurons and astrocytes, protects cKO P2 mice through the induction of 
PHD3 and subsequent control of the HIF-2α-activity. Other evidence for a prominent role of 
HIF-2α in the PHD2/HIF-1α-deficient background was supported by the two-fold increase of 
EPO in circulation in these mice compared to cKO P2 mice. Surprisingly, cKO P2/H1 mice did 
not show any significant change in hematocrit compared to cKO P2, again implying that the high 
RBC concentration alone was probably not the cause of their early death.  
In conclusion, we have shown through several loss-of-function mutations that conditional PHD2 
deficiency in kidney and brain results in an excessive HIF-2α-driven overproduction of EPO. 
However, HIF-1α serves as a protective factor in these mice, providing new insights to a 
potential interplay with HIF-2α and PHD3 (Figure 6D). Additionally, these findings have 
implications for pharmacological strategies that aim at inducing erythropoiesis. Whereas specific 
inhibition of PHD2 might be beneficial, compounds that simultaneously target all PHDs can 
ultimately be harmful.  
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Figure legends 
Figure 1. Conditional deficient PHD2 mice display severe HIF-2α -induced erythrocytosis. 
(A) Compared to WT mice, cKO P2 show profound redness of the snout and paws. (B) Body 
weight of WT and cKO P2 mice was measured on a weekly basis until adulthood. No significant 
difference was observed after week 8 (n = 5-11). (C) Percentage of red blood cell volume per 
blood volume (hematocrit-hct) from mice was measured every two weeks until adulthood, 
displaying highly significant differences from week 4 after birth (n = 5-10). (D) Hcts in cKO 
P2/H1 remained as high as in cKO P2 mice whereas cKO P2/H2 mice showed even slightly but 
significantly lower hcts than WTs (n = 6-15). (E and F) RBC count (n = 7-32) and hemoglobin (n 
= 6-22) concentration in freshly isolated blood samples demonstrate that HIF-2α but not HIF-1α 
induces erythrocytosis due to loss of PHD2. All data are mean ± s.e.m. *P < 0.05, **P < 0.01, 
***P < 0.001.  
 
Figure 2.  Loss of PHD2 in cKO P2 mice leads to induction of EPO in kidney and brain. (A) 
Erythropoietin (EPO) concentration in plasma measured by ELISA in the plasma of WT, cKO 
P2, cKO P2/H1 and cKO P2/H2 mice (n = 6-22). cKO mice contain on average 6 times more 
EPO in the circulation than their WT littermates, whereas cKO P2/H1 mice have over 17 times 
more EPO. No difference between WT and cKO P2/H2 was found. (B) mRNA levels in total 
extracts from kidney and brain (n = 5-15) is markedly induced compared to WT but not 
significantly different between cKO P2 and cKO P2/H1 mice because of the high variation 
between individual samples (n = 7-11). No difference between WT and cKO P2/H2 could be 
shown.  (C) The renal derived human cell line (REPC)
26
 was tested for the expression of EPO 
and CD68 grown under normoxic and hypoxic conditions via RT-PCR, showing the expected 
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EPO induction and expression of CD68 under both conditions, suggesting a potential link 
between cre-expression, PHD2 inactivation and subsequent EPO expression in these cell types. 
(D) Astrocytes isolated from the cerebral cortex of five day old pups show a significantly 
reduced PHD2 content in cKO P2 versus WT mice (n = 3). (E) Typical IHC on brain sections for 
PHD2 (red) with or without NeuN (green) show a majority of PHD2-negative neurons in the 
brain of cKO P2 mice (depicted by arrow heads) but not in WT. (F) WT and cKO P2 mice were 
lethally irradiated and received cKO P2 or WT bone marrow (BM) respectively. Hematocrits 
were measured 4 months after transfer. BM from either genotype did not change hcts in the 
recipient (n = 6-23). Scale bar in (E) represents 50µm All data are mean ± s.e.m. N.S. is not 
significant and *P< 0.05, *** P < 0.001.  
 
Figure 3. Erythrocytosis is mainly caused by extramedullary erythropoiesis in the spleen. 
(A and B) Representative sections of WT and cKO P2 spleens (H&E) show an extensive 
structural loss and an augmentation of nucleated cells in erythrocytotic cKO P2 mice. (C) Spleen 
weight of WT and cKO P2 mice (n = 10-16).  (D-G) Representative FACS staining profiles of (D 
and E) megakaryocyte-erythrocyte progenitors (MEP) (n = 6) and (F and G) erythroblasts (EB) 
(n = 7) in BM and spleen of WT and cKO P2 showing that the overproduction of RBCs is mainly 
executed in the spleen. Scale bars represent 500µm. All data are mean ± s.e.m. *P < 0.05, ***P < 
0.001. 
 
Figure 4. cKO P2 mice show thrombocytopenia but no early lethality, while cKO P2/H1 die 
prematurely. (A) Thrombocyte concentrations in the blood of WT and cKO P2 mice until 
adulthood reveal a significant reduction of circulating platelets per volume of blood in cKO P2 
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mice (n = 5-10). WT is represented by black squares and cKO P2 by red triangles. (B) 8-10 week 
old mice were bled and thrombocytes measured in a fixed volume of blood showing 
thrombocytopenia in cKO and cKO P2/H1 mice compared to WT and cKO P2/H2 mice (n = 6-
7). (C-D) WT and cKO P2 kidneys stained with acid Fuchsin orange-G show no signs of 
microvascular thrombosis suggesting that platelets are not trapped within blood clots. (E) 
Instead, the total blood volume of cKO P2 mice was significantly increased compared to WT 
mice (n = 9-10). (F) Nine cKO P2 mice (five females and four males) were kept for 20 months. 
Mice were bled every 4 months to measure hematocrits. No significant differences in hcts were 
found and none of the mice died before the end of the experiment. (G) cKO P2/H1 (n = 17) and 
cKO P2 (n = 15) mice were followed for 20 weeks. cKO P2/H1 mice began to die from week 
five after birth. By week sixteen, 16 out of 17 mice were deceased. No cKO P2 mice died during 
the course of this experiment. Scale bars represent 100 µm. All data are mean ± s.e.m. **P < 
0.01, ***P < 0.001. 
 
Figure 5. HIF1a serves as a protective factor to prevent brain damage. (A-C) IHC on brain 
sections from WT, cKO P2 and cKO P2/H1 for Iba1 (brown) showing more activated microglia 
cells in brain sections of a cKO P2/H1 mouse. (D-F) IHC on brain sections from a freshly 
deceased cKO P2/H1 mouse for (D) cleaved-caspase3 (cl-Casp3) (red), (E) neurons (NeuN) 
(green) and (F) a merged picture combined with DAPI (white arrows depict typical examples of 
cl-Casp3
+
 neurons). No obvious cl-Casp3 staining was detected in WT or cKO P2 brains (data 
not shown). (G) Expression profile (qRT-PCR) of different genes in the lysate of the entire brain 
of cKO P2 and cKO P2/H1 mice in relation to their respective WT littermates (n = 5-9). All data 
are mean ± s.e.m. *P< 0.05. Scale bars in (A-C) 100µm and (D-F) 50µm.  
31 
 
 
Figure 6. Mice deficient for PHD2 and PHD3 display erythrocytosis and die prematurely. 
(A) cKO P2/P3 mice show enhanced Hcts compared to their WT littermates (n = 5). (B) WT, 
PHD3
-/- 
and cKO P2/P3 mice were followed for 20 weeks. cKO P2/P3 mice began to die shortly 
after birth (n = 7). (C) Expression profile (qRT-PCR) of different genes in the lysate of the entire 
brain of cKO P2 and cKO P2/P3 mice in relation to their respective WT littermates. *p<0.05 is 
significantly different from cKO P2 samples (expression relative to their WT littermates) (n = 5-
7). (D) Schematic overview of the different genetic mouse models that were generated in this 
study showing non-lethal erythrocytotic cKO P2 mice that display a perfect balance between the 
protective HIF-1α activity and detrimental HIF-2α activity in the brain. In cKO P2/H1 mice this 
balance is disturbed in favor of the HIF-2α activity leading to early lethality in the mice. All data 
are mean ± s.e.m. *P< 0.05, **P < 0.01 
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Supplemental Figure 1. Production of CD68:icre-pA and expression profile of CD68:cre-PHD2f/f mice. 
(A) Schematic representation of the pUC19-CD68-icre-pA vector constructed using classical cloning 
methods (icre: improved cre). All cloning steps were sequence verified and functionality of the construct 
tested in the RAW264 cell line. (B) Different hematopoietic cells (Macrophages (MФ) and whole bone 
marrow (BM)) were isolated from WT and CD68:cre-PHD2f/f (cKO P2) mice and tested for the presence of 
PHD2 mRNA (n = 5-7). (C) Epithelial cells (colonocytes (Ep (C)) and keratinocytes (Ep (K)), lung endothelial 
cells (EC) and skin fibroblasts from newborns (Fb)) were isolated, (D) as well as lysates from different 
organs and tested for PHD2 mRNA content via qPCR (n = 5-7). (E) PHD1 and 3 expression levels in bone 
marrow (BM) and isolated epithelial cells out of colon and skin from WT and cKO mice (n = 3-6). No 
significant difference between both genotypes could be detected. All data are mean ± s.e.m. **P < 0.01 
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Supplemental Figure 2. Blood pressure and heart beat/hypertrophy in cKO P2 is not 
altered. (A-B) Blood pressure and heart beat of all mice were measure at the age of 8-12 
weeks via the non-invasive cuff-tail method. (n = 7-9) (C) Sections of the heart of both 
phenotypes were stained with H&E and thickness of the wall of both ventricles were 
compared. No significant difference between WT and cKO P2 mice was detected (n = 6-8). All 
data are mean ± s.e.m. N.S. is not significant. 
WT cKO P2
0
50
100
150
N.S.
S
y
s
to
lic
 b
lo
o
d
 p
re
s
s
u
re
(m
m
 H
g
)
WT cKO P2
0
200
400
600
N.S.
H
e
a
rt
 r
a
te
(b
e
a
ts
 p
e
r 
m
in
)
WT cKO P2
0
500
1000
1500
N.S.
T
h
ic
kn
e
s
s
 w
a
ll 
L
V
 (
µ
m
)
WT cKO P2
0
100
200
300
400 N.S.
T
h
ic
kn
e
s
s
 w
a
ll 
R
V
 (
µ
m
)
Supplemental Figure 3 
W
T
cK
O
 H
1
cK
O
 H
2
0
3
6
9
12 **
N.S
H
b
 (
m
m
o
l/
L
)
W
T
cK
O
 H
1
cK
O
 H
2
0
20
40
60
**
N.S.
H
e
m
a
to
c
ri
t 
(%
)
Supplemental Figure 3. Loss of HIF-2a leads to mild anemia. (A-C) All mice were bled at 
the age of 8 weeks. cKO H2 mice showed significantly lower hcts, RBC counts and 
hemoglobin than WTs or cKO H1 mice. This signifies the specific cre-activation in EPO 
producing cells driven by the hCD68 promotor and the role of HIF-2a in erythropoiesis (n = 6-
9). All data are mean ± s.e.m. N.S. is not significant and *** P < 0.001.  
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Supplemental Figure 4 
Supplemental Figure 4. cKO spleen is almost devoid of lymphocytes but not of myeloid cells. 
(A and B) B- and T-lymphocytes in spleen extracts from WT and cKO mice showing significant 
reduction in erythrocytotic mice (n = 4). (C and D) Conversely, lymph nodes (2 popliteal and 2 
inguinal) from cKO mice contain more B and T lymphocytes (n = 5). (E and F) No difference was 
detected in myeloid cells (macrophages and PMNs) in spleen (n = 5). (G) However, red pulp 
macrophages, a subtype responsible for the elimination of RBCs, is significantly induced in cKO 
mice in the spleen (n = 5). All data are mean ± s.e.m. *P < 0.05, **P < 0.01.  
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Supplemental Figure 5 
Supplemental Figure 5. cKO mice show thrombocytopenia but no reduction in 
its progenitors (A) Serum thrombopoietin (TPO) levels were measured via ELISA 
but show no difference between both genotypes (n = 7-14). (B and C) Megakaryocyte 
(MK) counting in H&E sections. cKO mice show no drop but rather an increase in total 
MKs per area. All data are mean ± s.e.m. N.S. is not significant and *P < 0.05. 
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Supplemental Figure 6 
Supplemental Figure 6. cKO mice are viable without obvious 
pathological defects. (A) A regressing cyst in a 20-month old female cKO 
mouse localized to an ovary (§) containing fibrin deposits (#) and a large 
calcificated area (@). (B) At 20 months of age these mice were sacrificed 
and different organs (Ki: kidney, Br.: brain, Li: Liver) from WT and cKO mice 
were isolated and stained with H&E. No obvious pathological defects could 
be observed. Scale bar in (A) represents 500 µm and (B) 50µm. 
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Supplemental Figure 7 
Supplemental Figure 7. Some cDKO1 mice display deformity of the 
head. A section of the brain of a (A) cDKO1 mouse with a dome-shaped 
skull (representative) versus a (B) WT littermate (H&E) showing the 
expanded ventricle indicating hydrocephalus. Scale bars represent 500 µm. 
Supplementary Tables 
TABLE 1. LIST OF PRIMERS USED TO GENOTYPE MICE 
hCD68 promoter 5’-CAACTGGTGCAGACAGCCTA-3’ 
cre recombinase 5’-CTGCACACAGACAGGAGCAT-3’ 
PHD2, exon2 5’-CGCATCTTCCATCTCCATTT-3’ 
PHD2, intron3 5’-GGCAGTGATAACAGGTGCAA-3’ 
PHD2, intron1 5’-CTCACTGACCTACGCCGTGT-3’ 
HIF1α, intron2 5’-GCAGTTAAGAGCACTAGTTG-3’ 
HIF1α, intron2 5’-GGAGCTATCTCTCTAGACC-3’ 
HIF2α, intron2 5’-CAGGCAGTATGCCTGGCTAATTCCAGTT-3’ 
HIF2α, intron2 5'-CTTCTTCCATCATCTGGGATCTGGGACT-3' 
HIF2α, intron1 5’-GCTAACACT GTACTGTCTGAAAGAGTAGC-3’ 
PHD3 fwd 5’-ATGGCCGCTGTATCACCTGTA T-3’ 
PHD3 Rev 5’-CCACGTTAACTCTAGAGCCACTGA-3’ 
 
TABLE 2. LIST OF PRIMERS USED FOR qRT-PCR 
PHD2, exon 3 5’-AAGCCCAGTTTGCTGACATT-3’ 
PHD2, exon 4 5’-CTCGCTCATCTGCATCAAAA-3’ 
HIF1α, exon 1 5’-GGCGAGAACGAGAAGAAAAA-3’ 
HIF1α, exon 2 5’-AAGTGGCAACTGATGAGCAA-3’ 
HIF2α, exon 1 5’-GGTTAAGGAACCCAGGTGCT-3’ 
HIF2α, exon 2 5’-GGAAGGAGAAATCCCGTGAT-3’ 
EPO, exon 4 5’-CACCAGAGACCCTTCAGCTT-3’ 
EPO, exon 5 5’-GTGGTATCTGGAGGCGACAT-3’ 
PHD3, exon 2 5’-GGCCGCTGTATCACCTGTAT-3’ 
PHD3, exon 4 5’-TTCTGCCCTTTCTTCAGCAT-3’ 
TNF-α, exon3 5’-CATCTTCTCAAAATTCGAGTGACAA-3′ 
TNF-α, exon4  5’-TGGGAGTAGACAAGGTACAACCC-3′ 
hCD68 ex1 fw (h=human) 5’-GCTACTGGCAGCCCCAGGG-3′ 
hCD68 ex2 rev 5’-GCTCTTGGTAGTCCTGTGG-3′ 
Glut1 (m-slc2a) fw 5’-GTCGGGGGCATGATTGGTTCCTT-3′ 
Glut1 (m-slc2a) rev 5’-CTCTTGGCCCGGTTCTCCTCGTTA-3′ 
IL1a denes fw 5’-CCATAACCCATGATCTGGAAGAG-3′ 
IL1a denes rev 5’-GCTTCATCAGTTTGTATCTCAAATCAC-3′ 
IL1b depot fw 5’-TGTGAAATGCCACCTTTTGA-3′ 
IL1b depot rev 5’-GGTCAAAGGTTTGGAAGCAG-3′ 
Nos2 fwd 5’-GTTCTCAGCCCAACAATACAAGA-3′ 
Nos2 rev 5’-GTGGACGGGTCGATGTCAC-3′ 
TGFb1f Q 5’-CAACCCAGGTCCTTCCTAAA-3′ 
TGFb1r Q 5’-GGAGAGCCCTGGATACCAAC-3′ 
Bnip3l fw  5’-CCAAGGCCAGCACATGAGAA-3′ 
Bnip3l rev  5’-GCTCTCAGTCAGAAGAAG-3′ 
VEGFA fw 5’- GGA GAG CAG AAG TCC CAT GA -3′ 
VEGFA rev 5’- ACA CAG GAC GGC TTG AAG AT -3′ 
IL12 p35 Fwd   5’-CTAGACAAGGGCATGCTGGT-3’ 
IL12 p35 Rev  5’-GCTTCTCCCACAGGAGGTTT-3’ 
CXCR 4 Gooss Fw 5’-GAAGTGGGTTCTGGAGACTAT-3’ 
CXCR 4 Gooss Rev 5’-TTGCCGACTATGCCAGTCAAG-3’ 
Adm depot fw 5’-TGGACTTTGGGGTTTTGCTA-3’  
Adm depot rev 5’-AACCAGCTTCATTCTGTGGC -3’   
TABLE 3. LIST OF PRIMERS OF HOUSEHOLD GENES USED FOR NORMALISATION WITH THE 
qRT-PCR ΔΔCt METHOD 
 
 
 
 
 
 
 
 
 
EF2, exon7/8 5’-AGGCCGCCATGGGTATTAAG-3’ 
EF2, exon8 5’-TTCAGACCTGTGGACACCACC-3’ 
β-actin, exon6 5’-GCTTCTAGGCGGACTGTTACTGA-3’ 
β-actin, exon6 5’-GCCATGCCAATGTTGTCTCTTAT-3’ 
mTBP, exon4 5’-TCTACCGTGAATCTTGGCTGTAAA-3’ 
mTBP, exon5 5’-TTCTCATGATGACTGCAGCAAA-3’ 
β2m, exon4 5’-ATGCACGCAGAAAGAAATAGCAA-3’ 
β2m, exon 4 5’-AGCTATCTAGGATATTTCCAATTTTTGAA-3’ 
ß2-microglobulin-h-s 5’-CTTTCAGCAAGGACTGGTCTTTC-3’ 
ß2-microglobulin-h-as 5’-TCACATGGTTCACACGGCAG-3’ 
hEF2var-s 5’-ATC CTC ACC GAC ATC ACC AAG-3’ 
hEF2var-as 5’-CTG CTC TGG ACA CTG GAT CTC-3’ 
